MedTrace Logo

A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg

NCT00241137 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3790

Last updated 2011-11-23

No results posted yet for this study

Summary

The purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of blood pressure reduction in a patient population of mild to moderate hypertensives

Conditions

Interventions

DRUG

valsartan

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceutical · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • Germany

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00241137 on ClinicalTrials.gov